Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
56.93
+0.72 (1.28%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Royalty Pharma Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 32,735 | 16,509 | 11,334 | 12,497 | 17,432 | 17,116 | |
Market Cap Growth | 110.23% | 45.66% | -9.30% | -28.31% | 1.85% | -11.89% |
Enterprise Value | 40,860 | 27,726 | 21,332 | 21,132 | 27,333 | 26,687 |
Last Close Price | 56.93 | 38.12 | 24.55 | 26.21 | 35.95 | 35.60 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 30.54 | 21.41 | 13.20 | 11.01 | 407.00 | 27.62 |
Forward PE | 10.35 | 7.70 | 6.10 | 7.47 | 10.32 | 13.00 |
PS Ratio | 12.91 | 6.94 | 5.01 | 5.31 | 7.79 | 7.48 |
PB Ratio | 3.71 | 1.70 | 1.10 | 1.24 | 1.83 | 1.67 |
P/TBV Ratio | 5.54 | 2.97 | 1.63 | 1.92 | 3.11 | 2.97 |
P/OCF Ratio | 11.00 | 6.63 | 4.09 | 4.18 | 8.13 | 8.48 |
PEG Ratio | 1.39 | 0.79 | 2.14 | 2.65 | 0.94 | 1.12 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 16.11 | 11.66 | 9.42 | 8.98 | 12.22 | 11.66 |
EV/EBITDA Ratio | 26.24 | 17.74 | - | 14.11 | 29.44 | 18.36 |
EV/EBIT Ratio | 26.32 | 17.78 | 16.51 | 14.16 | 29.62 | 18.65 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.92 | 0.92 | 0.74 | 0.61 | 0.75 | 0.69 |
Debt / EBITDA Ratio | 5.75 | 5.74 | - | 4.10 | 7.66 | 4.88 |
Net Debt / Equity Ratio | 0.83 | 0.86 | 0.64 | 0.56 | 0.56 | 0.48 |
Net Debt / EBITDA Ratio | 5.22 | 5.33 | - | 3.77 | 5.79 | 3.38 |
Asset Turnover | 0.13 | 0.13 | 0.13 | 0.14 | 0.13 | 0.14 |
Quick Ratio | 2.79 | 2.39 | 1.43 | 7.78 | 2.11 | 16.77 |
Current Ratio | 2.80 | 2.40 | 1.44 | 7.90 | 2.19 | 16.81 |
Return on Equity (ROE) | 13.96% | 13.20% | 13.03% | 17.34% | 2.33% | 12.32% |
Return on Assets (ROA) | 5.09% | 5.15% | 4.67% | 5.62% | 3.36% | 5.33% |
Return on Capital Employed (ROCE) | 8.10% | 8.20% | 7.60% | 9.20% | 5.90% | 8.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.48% | 4.67% | 7.58% | 9.08% | 0.25% | 3.62% |
Dividend Yield | 1.65% | 2.31% | 3.42% | 3.05% | 2.11% | 1.91% |
Payout Ratio | 50.42% | 49.06% | 43.83% | 31.57% | 778.21% | 46.02% |
Buyback Yield / Dilution | 3.88% | 4.99% | 1.46% | -37.66% | -5.59% | -10.48% |
Total Shareholder Return | 5.53% | 7.30% | 4.88% | -34.61% | -3.47% | -8.57% |